GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells by Marchal, J A et al.
The goal of cancer chemotherapy with classical drugs – the
destruction of the tumour cells – is often complicated by signifi-
cant toxicity. Differentiation therapy is a new approach to cancer
treatment which assumes that neoplastic transformation reveals
the inability of a cell population to couple proliferation and
differentiation signals. Induced differentiation modulates the cell
programme by transforming malignant cells into mature cells with
no proliferative potential (Sartorelli, 1985; Borden et al, 1993).
Cells mature, become differentiated, die, disappear and are
replaced by normal cells. The addition of differentiation treatment
to chemotherapy greatly improves the chance of long-term
survival (Degos, 1995). However, the development of multidrug
resistance (MDR) phenotype in tumour cells during treatment can
be the major obstacle in the differentiation therapy of cancer.
Although standard agents used in the treatment of tumours may
induce several mechanisms of drug resistance, classic MDR has
been related to the overexpression of the mdr1 gene, which
encodes P-glycoprotein. This protein, which acts as a drug efflux
pump, decreases the cellular accumulation of cytotoxic drug
(Germann, 1996; Skach, 1996).
New differentiative drugs developed from well-known chemical
structures endeavour to overcome the two main problems associ-
ated with classic chemotherapy: toxicity and the appearance of
resistance. Recent years have seen the development of prodrugs
designed to induce differentiation in various types of neoplasms
(Chen and Breitman, 1994). 5-Fluorouracil (5-FU) in combination
with other differentiating agents (Zupi et al, 1988) is able to induce
differentiation in tumour cells derived from human colon carci-
noma and leukaemia (Waxman et al, 1990, 1992; Lesuffleur et al,
1991a,b). However, 5-FU is highly toxic to both tumour and
normal cells, and it is therefore essential to search for derivatives
that mimic the action of 5-FU without producing undesirable side-
effects. The pyrimidine acyclonucleoside-like compound (R,S)-1-
{[3-(2-hydroxyethoxy)-1-isopropoxy]propyl}-5-fluorouracil
(GR-891) is a 5-FU acyclonucleoside-like prodrug that shows
little or no toxicity in vivo compared with 5-FU (Campos et al,
1996) (Figure 1).
Studies in rhabdomyosarcoma tumours, the most frequent soft
tissue malignancy in paediatric patients, have shown that the malig-
nant phenotype can be repressed to some degree, and that the
tumour cells can be induced to re-enter the differentiation process
(Gabbert et al, 1988; Aguanno et al, 1990; Crouch and Helman,
1991; De Giovanni et al, 1993). Few studies have been published
on drug-induced myogenic differentiation in rhabdomyosarcoma
chemotherapy (Lollini et al, 1989; Crouch et al, 1993; D’Amore et
al, 1994; Melguizo et al, 1995, 1996; Marchal et al, 1997). Other
pyrimidine analogues such as cytarabine arabinoside (Crouch et al,
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at low doses (22.5 mmol l–1 and 45 mmol l–1) and induced terminal myogenic differentiation in RD cells (a rhabdomyosarcoma cell line) treated
for 6 days. Changes in morphological features and in protein organization indicated re-entry in the pathway of muscular maturation. Moreover,
GR-891 increased adhesion capability mediated by the expression of fibronectin, and did not induce overexpression of P-glycoprotein, the
mdr1 gene product, implicated in multidrug resistance. New acyclonucleoside-like compounds such as GR-891 have important potential
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Universidad de Granada, E-18071 Granada, Spain1993) have recently been investigated as differentiating drugs for
rhabdomyosarcoma. Previously, we showed that these new 5-FU
acyclonucleosides are capable of inducing differentiation in
rhabdomyosarcoma cells (Gómez et al, 1997). These experiences
suggest that this type of tumour may be amenable to treatment by
differentiation therapy.
The aim of this study was to evaluate the potential role of GR-
891, a new pyrimidine acyclonucleoside-like compound, against
rhabdomyosarcomas. Our data demonstrate that GR-891 inhibits
proliferation, induces myogenic differentiation, increases the
expression of proteins specifically present in normally differenti-
ated skeletal muscle cells, and modifies the adhesion capacity of
these cells. In addition, this drug causes no modifications on mdr1
gene expression of RD cells.
MATERIALS AND METHODS
Cell culture
The rhabdomyosarcoma cell line RD (MacAllister et al, 1969),
derived from a human embryonic rhadomyosarcoma, was
obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA). RD cells were routinely maintained in
monolayer cultures at 37°C in an atmosphere containing 5%
carbon dioxide with Dulbecco’s modified Eagle medium (DMEM)
(Gibco, NY, USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco), 20 mmol l–1 L-glutamine, 3.5 mg ml–1 sodium bi-
carbonate, 4.5 g l–1 glucose, 250 U ml–1 ampicillin and 20 mg ml–1
streptomycin. The same batch of FBS was used for all experiments
to obviate variations in quality.
Drugs and drug treatments
After synthesis and purification of GR-891 (Campos et al, 1996),
stock solutions of GR-891 and 5-FU were prepared. The drugs
were dissolved in distilled water, sterilized by filtration, and stored
at –20°C. For each experiment, the stock solution was further
diluted in medium to the desired concentration. The cells were
detached from the surface of the tissue culture flasks with
phosphate-buffered saline (PBS)/EDTA (0.02%) and diluted in
Dulbecco’s medium to obtain cultures of 5 ´ 106 cells. RD cells
were exposed continuously to three different concentrations of GR-
891 and 5-FU: 22.5 mmol l–1, 45 mmol l–1 and 90 mmol l–1. Parallel
cultures of RD cells in medium without drugs were used as
controls. The medium in both control and drug-treated cultures was
replaced every 48 h, and the cultures were maintained and exam-
ined every 24 h for 6 days. Separate RD cell cultures were treated
with 22.5 mmol l–1, 45 mmol l–1 and 90 mmol l–1 for 3 days, after
which GR-891 and 5-FU were removed from the culture media.
These cells were allowed to recover log phase growth in normal
standard media and were then retreated with the drugs for 6 days.
Assessment of growth properties in vitro
Eighteen replicate culture flasks (25 cm2) (Greiner, Nürtingen,
Germany) containing parental RD cells (1 ´ 106) were exposed to
growth medium supplemented with 22.5 mmol l–1, 45 mmol l–1 or
90 mmol l–1 of GR-891 or 5-FU. As a control, culture flasks were
seeded with cells in standard growth medium. In each experiment,
cells from the culture flasks with each different drug concentra-
tion, and three flasks with cells growing in drug-free medium,
were harvested separately every 24 h for 6 days. Cell viability was
assayed by the trypan blue exclusion test. The number of cells
harvested was determined in a model ZBI Kontron Coulter
counter.
In vitro morphology
RD cells were observed with an inverted light microscope and a
transmission electron microscope before and after treatment with
GR-891 or 5-FU at a concentration of 22.5 mmol l–1, 45 mmol l–1 or
90 mmol l–1. Optic phase-contrast photographs were taken with a
Nikon TM Phase Contrast-2, ELWD 0.3 inverted microscope. The
number of myotube-like giant cells was counted by phase-contrast
microscopy at intervals of 24 h. Cells that contained three or more
nuclei were classified as myotube-like giant cells. For trans-
mission electron microscopy, RD cells were treated according to
Melguizo et al (1995) and ultrathin sections were cut parallel and
perpendicular to the surface of the flask. The sections were
contrasted with uranyl acetate/lead citrate and examined in a
Hitachi H 7000 transmission electron microscope (TEM).
Adherent tumour cells on coverslips were fixed for scanning
electron microscopy (SEM) with 2.0% glutaraldehyde, dehydrated
in graded concentrations of ethanol, and dried using the critical
point method. These preparations were coated with platinum and
observed with a Hitachi S-800 scanning electron microscope.
Fluorescence-activated cell sorting (FACScan)
Non-treated cells and RD cells treated for 6 days were prepared for
FACScan as described elsewhere (Melguizo et al, 1996). The cells
were incubated for 30 min at 4°C with the anti-desmin (dilution
1:200) and anti-vimentin (dilution 1:200) monoclonal antibodies
(mAbs) (Sigma, St Louis, MO, USA), then washed twice in cold
PBS and reincubated with fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG (Sigma) at a dilution of 1:50 for FACS
analysis.
Immunofluorescent cytochemistry
Cultured RD cells were analysed after 6 days of treatment with
22.5 mmol l–1, 45 mmol l–1 or 90 mmol l–1 of GR-891 and 5-FU. The
cells were washed several times with PBS at pH 7.2, fixed with
methanol at 4°C for 10 min, washed three times in PBS and incu-
bated with EA-53 anti-a-actinin mAb (dilution 1:200) (Sigma)
and FN-15 anti-fibronectin mAb (dilution 1:200) (Sigma) at 37°C
for 15 min in a humidified chamber. The first incubation was
followed by washing four times in PBS and a second incubation at
37°C in a dark, humidified chamber with a 1:50 dilution of FITC-
conjugated goat anti-mouse IgG (Sigma) during 30 min. After a
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Figure 1 Structure of (RS)-1-{[3-(2-hydroxyethoxy)-1-isopropoxy]propyl}-5-
fluorouracil) (GR-891)final 10-min washing in PBS, the slides were mounted at pH 7.2 in
FA mounting fluid (Difco Laboratories, Detroit, MI, USA). All
cells were examined under a Nikon HFX-IIA light microscope for
epifluorescence studies. Photographs were taken with a Nikon FX-
35WA camera using Kodak TMAX 400 ASA paper.
PCR evaluation of mdr1 mRNA levels
Total RNA was obtained from untreated and treated RD cells
according to Maniatis et al (1982) and reverse transcription was
carried out with mdr1 or b2-microglobulin (b2m) primers as
described by Nootan et al (1990). Levels of mdr1 mRNA were
estimated relative to b2m mRNA using a modification of the RNA
PCR method (Fuqua et al, 1990). The polymerase chain reaction
(PCR) products obtained were loaded onto 2% agarose gels and
visualized by ethidium bromide staining.
Statistical analyses
The data derived from growth curves were subjected to analysis of
variance with two independent factors. Student’s t-test was used to
analyse the differences between control and treated RD cells after
FACS analysis. All data are means ± s.e.m. of three separate exper-
iments, and a P-value less than or equal to 0.05 was considered
significant.
RESULTS
Modification of growth rate by GR-891 and 5-FU
Treatment with GR-891 and 5-FU inhibited proliferation of the RD
cell line. All concentrations of the drugs had a substantial inhibitory
effect on growth during the first 3 days in comparison with the
growth rate of control cells (Figure 2). After this period, prolifera-
tion was inhibited until day 6. Inhibition was significantly greater in
cells treated with 22.5 mmol l–1, 45 mmol l–1 or 90 mmol l–1 5-FU than
in cultures treated with different concentrations of GR-891. Cells
treated once with GR-891 and 5-FU reached logarithmic growth
appoximately 1 week after the drug was removed from the culture
medium. Re-exposure of these logarithmically growing RD cells to
drugs for an additional 6 days resulted in complete growth suppres-
sion that was no longer reversible after drugs were removed a
Differentiation therapy in RMS cells with GR-891 809
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Figure 2 Effect of treatment with GR-891 (A) and 5-FU (B) on the
proliferation of rhabdomyosarcoma (RD) cells. Dose–response growth curves
of untreated RD cells (n) and RD cells treated with 22.5 mmol l–1 (s s),
45 mmol l–1 (l) or 90 mmol l–1 (u) GR-891 and 5-FU respectively. Results are
the means of three experiments conducted in triplicate; bars, s.e.
Figure 3 Morphological changes caused by GR-891 in a human
rhabdomyosarcoma cell line RD after 6 days of treatment. Phase-contrast
microscopy of small spindle-shaped mononuclear cells under standard
growth conditions. Typical cells of the RD parental cell line formed confluent
aggregates, and grew in a monolayer (A) (´ 6). After treatment with GR-891
(22.5 mmol l–1), RD cells became elongated and grew in parallel (B) (´ 6).
These cells showed contact at points of the cell membrane and formed
myotube-like giant cells (C and D) (´ 12). Some cells occasionally developed
many cytoplasmic projections which gave them an outline reminiscent of
neuronal cells (E) (´ 12)second time from the culture medium (data not shown). After treat-
ment, the viability of cells in both control cultures and cultures
treated with 22.5 mmol l–1, 45 mmol l–1 or 90 mmol l–1 of GR-891 was
>90%; however, there was a decrease in the percentage of viable
cells to 73% in cultures treated with 5-FU.
In vitro morphology
Observations with phase-contrast microscopy showed that
parental RD cells had characteristics of undifferentiated cells
(Figure 3A). During the first 2 days of treatment, cells growing
with GR-891 and 5-FU showed no morphological changes in
comparison with parental RD cells. However, after the 3rd day and
until day 6, most of the cell population treated with 22.5 mmol l–1
or 45 mmol l–1 GR-891 grew in a whorl-like or a parallel pattern
(Figure 3B), and showed an evident increase in the proportion of
elongated and multinucleated cells (myotube-like giant cells)
which represented up to 65% of the cell population (Figure 3C and
D). Some cells developed many branching processes which gave
them a characteristic neurite-like appearance (Figure 3E). In
contrast, cell cultures treated with any dose of 5-FU showed few
myotube-like giant cells (< 10%) and a larger proportion (82%) of
dead cells after 6 days of treatment (not shown).
Examination of the parental RD cell line with SEM showed a
variety of more or less elongated and polygonal shapes (Figure
4A). In contrast, the RD cells treated with 22.5 mmol l–1 or
45 mmol l–1 of GR-891 showed an evident increase in the cyto-
plasm, which adhered strongly to the substrate. These doses also
increased the size and number of phylopodia and membrane folds
(Figure 4B). Nevertheless, the most important characteristic of
myogenic differentiation was the appearance of myotube-like
giant cells in which the parallel arrangement of myofibrils along
their longitudinal axis was evident (Figure 4C). In contrast, 5-FU
led to the appearance of rounded cells with a very irregular
contour and a surface split up into great portions which seem to
show a current necrotic process (not shown).
RD cells treated for 6 days with GR-891 showed typical ultra-
structural features of myogenic differentiation. In contrast to the
RD parental cell line, treated cells had multiple nuclei consistent
with giant cell formation, and the cytoplasm occupied large areas
and contained increased numbers of oganelles including polyribo-
somes and rough endoplasmic reticulum (Figure 5A). A large
number of glycogen deposits in clusters and elongated mitochon-
dria with clear matrices and dilated cristae were visible. Treated
cells contained many lipid vesicles throughout the cytoplasm and
near the nucleus (Figure 5B), increased amounts of intermediate
filaments (Figure 5C) and parallel myofilaments which tended to
appear in well-defined bundles (Figure 5D) with electron-dense
zones similar to Z-bands (Figure 5E). These changes were seen
mainly in RD cells treated with 22.5 mmol l–1 or 45 mmol l–1 GR-
891; similar features were seen in cells treated twice with these
concentrations. In contrast, in cultures treated with 5-FU, few cells
displayed these changes, and a larger proportion of cells showed
characteristics of reduced cell viability (not shown).
Modifications in intermediate filaments
Quantitative data on the changes in desmin and vimentin expres-
sion in cell line RD after 6 days of treatment with different concen-
trations of GR-891 and 5-FU were provided by FACS analysis
(Table 1). Desmin and vimentin expression showed more evident
changes in RD cells treated with 22.5 mmol l–1 or 45 mmol l–1 of
GR-891 than with 90 mmol l–1. There was a significant increase in
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Figure 4 Scanning electron micrograph images of untreated and treated
RD cells for 6 days with 22.5 mmol l–1 or 45 mmol l–1 GR-891. Morphological
characteristics of RD cells growing in standard medium (A) (´ 1350).
Membrane changes in RD cells treated with 45 mmol l–1 GR-891. Note the
appearance of phylopodia (thick arrows) and the attachment of cells to the
substrate (stars) (B) (´ 2100). Appearance of myotube-like giant cells
showing myofibrils along the longitudinal axis (C) (´ 3000) in RD cells treated
with 22.5 mmol l–1 GR-891
Table 1 FACScan analysis of desmin and vimentin in the RD cell line after induction with GR-891 and 5-FU
Control GR-891 (mM) 5-FU (mM)
22.5 45 90 90
Desmin (%) 29.93 ± 2.1 68.80 ± 1.6a,c 63.04 ± 2.0a,c 47.60 ± 1.8b 48.52 ± 2.5b
Vimentin (%) 86.30 ± 3.2 40.79 ± 2.4a,c 57.51 ± 3.3a,d 80.21 ± 2.2 72.56 ± 3.5
All data are means ± s.e.m. of four independent determinations. Significance was determined by comparison of the means with Student’s t-test. aSignificantly
different (P < 0.001) compared with parental RD. bSignificantly different (P < 0.005) compared with parental RD. cSignificantly different (P < 0.001) compared
with RD cells treated with 5-FU. dSignificantly different (P < 0.005) compared with RD cells treated with 5-FU.desmin expression in RD cells treated with the lowest concentra-
tions; however, only 29.93% of the parental RD cells expressed
desmin. In comparison with the parental cell line, the percentage
of vimentin-positive cells decreased significantly after treatment
with 22.5 mmol l–1 or 45 mmol l–1 GR-891, whereas no significant
change was found in RD cells growing in the presence of
90 mmol l–1 of GR-891. RD cells treated with 90 mmol l–1 5-FU
showed a significant increase in the labelling for desmin in relation
to control RD cells. In contrast, no modifications were found in
vimentin expression (Table 1). With doses of 22.5 mmol l–1 or
45 mmol l–1 5-FU, we also found increased expression of desmin
but no change in vimentin (data not shown).
Immunofluorescent cytochemistry
Indirect immunofluorescence studies showed that the parental RD
cell line expressed a-actinin in the plasma membrane, and scattered
throughout the interior of the cells (Figure 6A). The expression of
fibronectin was practically undetectable: in the cells in which this
appeared, it was unevenly distributed as small round plaques
throughout the cytoplasm and cellular membrane (Figure 6B).
Cells induced with the lowest concentrations of GR-891 showed
intense labelling for a-actinin, which was well organized along
phylopodia and the cytoplasmatic prolongations of myotube-like
giant cells. Moreover, this protein appeared in the cytoplasm as
parallel rows of immunofluorescent dots along the longitudinal
axis of the cells (Figure 6C). The 90 mmol l–1 concentration of both
GR-891 and all doses of 5-FU led to slight modifications in the
expression and distribution of the a-actinin, with more intense
labelling than in the non-treated cells (not shown).
In cells induced with GR-891 and 5-FU, both the intensity of
labelling in most cells and the size of the adhesion plaques were
greater than in control cells. Adhesion plaques were distributed
throughout the length of the cells, and in more differentiated cells we
observed incipient extracellular expression on the rim of the cyto-
plasmatic prolongations. These changes were more evident in cells
induced with the lowest concentrations of GR-891 (Figure 6D).
Determination of mdr1 expression by reverse
transcription polymerase chain reaction (RT-PCR)
The parental RD cell line yielded a weak PCR product for mdr1
(Figure 7). After induction for 6 days with any of the drug doses,
there were no modifications in the PCR product for mdr1 in the
parental RD cell line. To demonstrate the integrity of the RNA
preparations, PCR was performed using b2m primers, and found to
be of the same intensity. PCR amplification of b2m demonstrated
that the number of transcripts in the parental RD cell line and in
RD cells treated with GR-891 and 5-FU was not the result of RNA
degradation.
DISCUSSION
New anti-cancer pyrimidine acyclonucleoside-like compounds
synthesized in our laboratory (Campos et al, 1996; Gómez et al,
1997) act as prodrugs of 5-FU, and can be phosphorylated by the
corresponding kinases and subsequently incorporated into RNA.
GR-891 can release other substances with anti-tumour activity
such as acrolein (Farquhar et al, 1995) and have low acute and
chronic toxicity in vivo (Campos et al, 1996).
Differentiation therapy in RMS cells with GR-891 811
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Figure 5 Transmission electron micrographs of RD cells treated for 6 days
with GR-891 (22.5 mmol l–1). Multinucleated giant cell with nucleoli and
increased numbers of cytoplasmic organelles (A) (´ 2500). RD cells showing
morphological changes of myogenic differentiation characterized by
numerous lipid vesicles (B) (´ 2500), highly organized intermediate filaments
in the cytoplasm (C) (´ 20 000) and abundant myofilament bundles (D)
(´ 8000) with zones similar to Z-bands (E) (´ 32 500)
Figure 6 Immunofluorescence micrographs of untreated and GR-891-
treated RD cells for 6 days with 22.5 mmol l–1. Low expression of a-actinin (A)
(´ 50) and fibronectin (B) (´ 50) in RD cells growing under standard
conditions. Treated RD cells showing intense labelling for a-actinin along the
longitudinal axis of the cell (C) (´ 50), and for fibronectin. Adhesion plaques
AB
C DThe results presented here demonstrate that GR-891 is able
to induce myogenic differentiation in rhabdomyosarcoma cell
cultures, in which normal differentiation is presumably interrupted
resulting in uncontrolled cell growth and a malignant phenotype
(Hazelton et al, 1987). This action on rhabdomyosarcoma differ-
entiation has been recently shown by us using other 5-FU
acyclonucleosides (Gómez et al 1997).
Rhabdomyosarcoma cells treated with 5-FU showed evident
growth inhibition after 48 h, and decreased cell viability for as
long as 6 days after treatment. This can be explained by the cyto-
toxic effect of 5-FU on this type of tumour, as was previously
shown for other cell lines (Zupi et al, 1988; Waxman et al,
1990). In contrast, growth inhibition caused by 22.5 mmol l–1 or
45 mmol l–1 GR-891 was less marked and appeared later; cell
survival after 6 days was 90%. Rhabdomyosarcoma cells treated
with these doses become phenotypically more mature, and show
characteristics of adult muscle cells (Gundersen et al, 1989) that
indicate unequivocal features of myogenic differentiation as has
been shown with other chemotherapeutic agents (Crouch et al,
1993; Melguizo et al, 1995; Marchal et al, 1997). The proportion
of elongated and multinucleated giant cells increased, and these
cells formed myotube-like giant cells. These structures contained
features suggestive of myofibrils: scanning electron microscope
images showed parallel bands which protruded along the longitu-
dinal axis of the cell membrane. Ultrastructural changes included
the appearance of an intense network of myofilaments arranged in
structures reminiscent of Z-bands.
Morphological changes in RD cells were accompanied by modi-
fications in the expression of differentiation markers (Carter et al,
1989; Prados et al, 1993; Wijnaendts et al, 1994). Treatment with
lower doses of GR-891 modified the expression of desmin,
vimentin and a-actinin, leading to a greater degree of organization
of myofilaments in treated cells with a gradual substitution of
vimentin by desmin and a uniform, linear distribution of a-actinin
filaments along the actin myofilaments. These changes suggest
that RD cells had re-entered the programme of muscle maturation
and subsequently underwent a process similar to myogenesis
(Burridge and Feramisco, 1981; Capetanaki et al, 1984;
Wijnaendts et al, 1994). Minor changes in the degree of protein
organization were observed with 5-FU, suggesting that its cyto-
toxic effect (Waxman et al, 1990, 1992; Lesuffleur et al, 1991a,b)
hindered complete differentiation.
Because cells that had grown in the absence of the drug after
3 days of treatment had a proliferative rate similar to that of
untreated cells and showed no morphological changes, our results
suggest an active induction of differentiation, as has been
proposed for other drugs (Chen and Breitman, 1994; D’Amore et
al, 1994; Marchal et al, 1997), rather than selective destruction of
undifferentiated cells. Moreover, within the parental cell popula-
tion, we found no pre-existing differentiated population that might
have indicated selective destruction.
The process of myogenic differentiation induced in the RD cell
line by GR-891 was accompanied by increases in the expression,
distribution and size of fibronectin plates. This protein of
fibronexus is essential for the intercellular junction between
myoblasts (Eyden, 1993), and takes part in the early phases of
alignment and fusion of muscle cells (Le Moigne et al, 1990; Melo
et al, 1996) and in subsequent morphological and structural
changes during differentiation (Volk et al, 1990; Enomoto et al,
1993). Cell-substrate contacts and cell–cell interactions depend on
the expression of fibronectin in rhabdomyosarcoma cells; both of
these phenomena are related to the stage of maturation (Vogel et
al, 1991) and with metastatic capacity (Langbein et al, 1990). The
increase in fibronectin expression induced in RD cells by GR-891
suggests an increased degree of differentiation and a loss of
metastatic potential. This supports the hypothetical inverse rela-
tionship between cancer malignancy and the degree of tumour
differentiation. In rhabdomyosarcomas, Herrera et al (1995)
showed that more differentiated cell lines were non-invasive and
non-metastatic.
GR-891 did not increase the expression of the mdr1 gene, in
contrast with other agents classically used to treat rhabdomyosar-
comas. Although other drugs can increase the degree of cell differ-
entiation, they also lead to mdr1 overexpression (Prados et al,
1996, 1998). Our findings indicate that GR-891 does not induce
resistance, at least not via increased mdr1 expression. This repre-
sents an important potential advantage over other chemothera-
peutic agents used to treat this type of tumour. Classic
chemotherapeutic agents induce the expression of P-glycoprotein,
which reduces the levels of the drug in the cell, and thus interferes
with the effectiveness of these agents in inducing re-entry into the
normal differentiation pathway (D’Amore et al, 1994; Melguizo et
al, 1995).
In conclusion, we evaluate the potential role of GR-891, a new
pyrimidine acyclonucleoside-like compound, for differentiation
therapy against rhabdomyosarcomas. Our results in rhab-
domyosarcoma cell cultures show that this new 5-FU prodrug
inhibits cellular proliferation, induces morphological and ultra-
structural changes typical of myogenic differentiation, and has
limited cytotoxic effects. The increase in fibronectin expression
suggests a decrease in the metastatic capacity of rhabdomyosar-
coma cells. The low toxicity of GR-891 and the fact that it does
not induce the MDR phenotype are significant advantages in
comparison with 5-FU and other agents used in tumour differenti-
ation therapy.
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Figure 7 Reverse transcriptase PCR of mdr1 mRNA expression in RD
cells (A) and b2m mRNA determined as a control for the PCR technique (B).
Lane 1, untreated RD cells; lane 2, RD cells treated with 90 mmol l–1 5-FU;
lanes 3–5, RD cells treated with GR-891 at a dose of 22.5 mmol l–1,
45 mmol l–1 or 90 mmol l–1 respectively
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